Course

Family Planning & Pregnancy Issues in RA

We will explore emerging standards for the care of pregnant women with RA, including the role of new drug labeling rules and pregnancy registries in developing a better understanding of pregnancy-related drug safety. We will also explore considerations for women who are breastfeeding as well as for male patients with RA who are making family planning decisions.

0 out of 5 steps completed0%
0 Lessons

Family Planning & Pregnancy Issues in RA

PROVIDED BY

Support for this activity has been made possible through educational grants from Lilly and Pfizer

TARGET AUDIENCE

This activity has been designed to meet the educational needs of nurses and nurse practitioners. Other healthcare providers may also participate.

ACTIVITY DESCRIPTION

In this issue of Rheumatology Nurse Practice, we will explore emerging standards for the care of pregnant women with RA, including the role of new drug labeling rules and pregnancy registries in developing a better understanding of pregnancy-related drug safety. We will also explore considerations for women who are breastfeeding as well as for male patients with RA who are making family planning decisions.

LEARNING OBJECTIVES

After participating in the activity, learners should be better able to:

  • Assess the expanded role of rheumatology providers in providing drug-appropriate information to patients who are pregnant or trying to get pregnant in light of the new Pregnancy and Lactation Labeling Rule
  • Analyze results from key registry studies that have explored possible predictors of clinical status among patients with RA during and following pregnancy
  • Discuss appropriate guidance that should be offered to both women and men with RA making family planning decisions
  • Develop a checklist of key information to suggest to new parents with RA that with help ease their transition into parenthood while keeping their disease under control

DISCLOSURE STATEMENT

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

RELATIONSHIPS ARE ABBREVIATED AS FOLLOWS

E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
C: Consultant
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
H: Honoraria
O: Other

DISCLOSURES AS FOLLOWS

Jacqueline Fritz, RN, MSN, CNS, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Horizon, Momenta Pharmaceuticals/SB.

Cathy Patty-Resk, MSN, RN, CPNP-BC, RN-BC, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Iris Zink, MSN, NP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Crescendo Biosciences, Horizon/SB; Pfizer/C.

Elizabeth Kirchner, CNP, RN-BC, as disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Horizon, Novartis, UCB, Lilly, GlaxoSmithKline, Boehringer Ingelheim/AB; Crescendo Biosciences/SB.

INDEPENDENT CLINICAL PEER REVIEWER

This newsletter was reviewed by Carrie Beach, RN, BSN. Ms. Beach has disclosed the following relationships: Pfizer, Horizon, Novartis/A.

OFF-LABEL PRODUCT DISCLOSURE

There will be no discussion of investigational and/or off-label use of pharmaceutical products or devices within this activity.

PLANNING COMMITTEE

Kim Cheramie, MSN, RN-BC, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Anne Jacobson, MPH, CHCP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

ACCREDITATION AND CREDIT DESIGNATION

Nurses

Rheumatology Nurses Society is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Rheumatology Nurses Society designates this educational activity for 3.42 total contact hours and 1.15 CNE pharmacotherapeutic contact hours.

METHOD OF PARTICIPATION

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please go to rnsnurse.com/rnpce and complete the post-test (achieving a passing grade of 70% or greater) and program evaluation. Your certificate will be emailed to you upon completion.

COPYRIGHT

© 2018. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).